U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07361094) titled 'Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases' on Jan. 04.
Brief Summary: Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, leading to chronic inflammation and damage to organs such as the kidneys, lungs, muscles, nerves, or blood cells. Although many treatments are available, some patients do not respond adequately or experience repeated disease flares despite long-term therapy. New treatment approaches are therefore needed for patients with relapsed or refractory autoimmune diseases. This study is an exploratory clinical trial designed to evaluate the s...